Professor Stefan H Hohnloser (J. W. Goethe University, Frankfurt, DE) discusses The ELIMINATE-AF Trial - Uninterrupted Edoxaban versus Vitamin K Antagonists for Ablation of Atrial Fibrillation at DGK 2019.
1. What is the ELIMINATE-AF and why was it initiated?
2. What are the advantages of using NOACs compared to VKAs?
3. What are your findings?
4. What further research, in your opinion, is needed?
5. What are the implications for clinical practice?
Videographers: Mike Knight, Tom Green
Interviewer: Rob Barclay
Filmed on site at DGK 2019 by Radcliffe Cardiology.